146 related articles for article (PubMed ID: 30444366)
1. Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.
Jiang ZY; Lu MC; You QD
J Med Chem; 2019 Apr; 62(8):3840-3856. PubMed ID: 30444366
[TBL] [Abstract][Full Text] [Related]
2. Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy.
Lin H; Qiao Y; Yang H; Nan Q; Qu W; Feng F; Liu W; Chen Y; Sun H
Future Med Chem; 2020 Feb; 12(3):243-267. PubMed ID: 31950858
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs.
Telkoparan-Akillilar P; Suzen S; Saso L
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022969
[TBL] [Abstract][Full Text] [Related]
4. The Dual Roles of NRF2 in Cancer.
Menegon S; Columbano A; Giordano S
Trends Mol Med; 2016 Jul; 22(7):578-593. PubMed ID: 27263465
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
Xue D; Zhou X; Qiu J
Biomed Pharmacother; 2020 Nov; 131():110676. PubMed ID: 32858502
[TBL] [Abstract][Full Text] [Related]
6. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
7. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Nrf2 promotes the antitumor effect of Pinelliae rhizome in papillary thyroid cancer.
Du Z; Wang Q; Ma G; Jiao J; Jiang D; Zheng X; Qiu M; Liu S
J Cell Physiol; 2019 Aug; 234(8):13867-13877. PubMed ID: 30697724
[TBL] [Abstract][Full Text] [Related]
10. Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review).
Zhu J; Wang H; Fan Y; Lin Y; Zhang L; Ji X; Zhou M
Oncol Rep; 2014 Aug; 32(2):443-50. PubMed ID: 24926991
[TBL] [Abstract][Full Text] [Related]
11. Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?
Catanzaro E; Calcabrini C; Turrini E; Sestili P; Fimognari C
Expert Opin Ther Targets; 2017 Aug; 21(8):781-793. PubMed ID: 28675319
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.
Zhang J; Su L; Ye Q; Zhang S; Kung H; Jiang F; Jiang G; Miao J; Zhao B
Oncotarget; 2017 Jan; 8(5):7625-7636. PubMed ID: 28032588
[TBL] [Abstract][Full Text] [Related]
13. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Manandhar S; Choi BH; Jung KA; Ryoo IG; Song M; Kang SJ; Choi HG; Kim JA; Park PH; Kwak MK
Free Radic Biol Med; 2012 May; 52(9):1773-85. PubMed ID: 22387177
[TBL] [Abstract][Full Text] [Related]
14. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.
Namani A; Li Y; Wang XJ; Tang X
Biochim Biophys Acta; 2014 Sep; 1843(9):1875-85. PubMed ID: 24851839
[TBL] [Abstract][Full Text] [Related]
16. Potential Applications of NRF2 Inhibitors in Cancer Therapy.
Panieri E; Saso L
Oxid Med Cell Longev; 2019; 2019():8592348. PubMed ID: 31097977
[TBL] [Abstract][Full Text] [Related]
17. Activating or Inhibiting Nrf2?
Chu XY; Liu YM; Zhang HY
Trends Pharmacol Sci; 2017 Nov; 38(11):953-955. PubMed ID: 28886953
[TBL] [Abstract][Full Text] [Related]
18. Targeting transcription factors for cancer prevention--the case of Nrf2.
Colburn NH; Kensler TW
Cancer Prev Res (Phila); 2008 Aug; 1(3):153-5. PubMed ID: 19138949
[No Abstract] [Full Text] [Related]
19. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1.
Na HK; Surh YJ
Free Radic Biol Med; 2014 Feb; 67():353-65. PubMed ID: 24200599
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
